USE OF A PREPARATION BASED ON AN ANTIBODY DIRECTED AGAINST A TUMOR-ASSOCIATED GLYCOSYLATION
The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation.
1 - 23 . (canceled)
24 . A method of treating a patient to reduce or inhibit the growth of tumor cells in a cancer by inhibiting glycosylated tumor cell receptors comprising administering to a patient an antibody directed against a tumor-cell receptor associated glycosylation antigen, wherein said antibody inhibits MAPK activation in said tumor cells and thereby inhibits activated MAPK mediated cell division, and wherein said antibody does not inhibit said glycosylated receptor from binding to its ligand, wherein said antibody is IGN311 or ABL364.
25 . A method for inhibiting tumor cell division in a patient comprising administering to said patient an amount of antibody IGN311, antibody ABL364 or a combination thereof effective to inhibit erbB receptor mediated MAPK activation in said tumor cells and thereby inhibit cell division, wherein said IGN311 and/or ABL364 antibodies do not inhibit erbB binding to its ligand.
26 . A method for stimulating a chemotherapeutic agent mediated lysis of dormant tumor cells, micrometastases or both in a patient comprising administering to said patient an antibody directed against an erbB receptor glycosylation antigen in combination with chemotherapeutic agent, wherein:
said antibody self-aggregates at or above a threshold concentration, and
said antibody is administered to said patient in a concentration at or above said self-aggregation concentration, thereby providing a growth stimulus to said dormant tumor cells and/or micrometastases, and
said growth of said tumor cells and/or micrometastases mediate said stimulation of said tumor cell and/or micrometastases lysis by said chemotherapeutic agent.
27 . The method of claim 26 , wherein said antigen is Lewis x, Lewis b, Lewis-y, sialyl-Tn, Tn antigen, GloboH, KH1,TF antigen or an alpha-1,3-galactosyl epitope Y.
28 . The method of claim 26 , wherein said chemotherapeutic agent is radiation.
29 . The method of claim 26 , wherein said antibody is an IgG3 antibody.
30 . The method of claim 26 , wherein said growth stimulus comprises a mitogenic stimulation of said tumor cell or micrometastases mediated by activated MAPK.
31 . The method of claim 27 , wherein said antigen is Lewis-y.
32 . The method of claim 30 or 31 , wherein said antibody is ABL364.
33 . The method of claim 32 , wherein said antibody is administered at a concentration of 1 μM or more.
34 . A method of treating a patient to reduce or inhibit the growth of tumor cells in a cancer by inhibiting glycosylated tumor cell receptors comprising administering to a patient a preparation consisting essentially of an antibody directed against a receptor comprising a tumor-associated glycosylation.